Projected outcomes averted by means of the quadrivalent vaccine and expected reductions in expenditure
| Outcomes | Annual expected number of events | Number of events prevented with the quadrivalent vaccine | Reduction in expenditure (€ million) |
| Abnormal pap smears | 415 000 | 258 337 | 3.8 |
| Colposcopies | 116 000 | 76 909 | 19.2 |
| LSIL and ASCUS | 91 000 | 56 648 | 22.7 |
| HSIL | 13 700 | 9097 | 8.2 |
| Cervical cancer | 4000 | 2988 | 49.9 |
| Genital warts | 125 000 | 115 625 | 27.8 |
| Total | 764 700 | 519 604 | 131.6 |
In this multicohort model, a vaccination coverage rate of 80% was assumed.19 20 Reductions were calculated at the peak efficiency of the vaccination programme. A cross-protection effect of the quadrivalent vaccine was also considered.
ASCUS, Atypical Squamous Cells of Undetermined Significance; HSIL, High-grade Squamous Intraepithelial Lesions; LSIL, Low-grade Squamous Intraepithelial Lesion.